Fiche publication
Date publication
mars 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BRASSART-PASCO Sylvie
,
Dr MONBOISSE Jean-Claude
,
Pr RAMONT Laurent
,
Dr THEVENARD-DEVY Jessica
Tous les auteurs :
Thevenard J, Ramont L, Mir LM, Dupont-Deshorgue A, Maquart FX, Monboisse JC, Brassart-Pasco S
Lien Pubmed
Résumé
The NC1 domains from the different alpha(IV) collagen chains were found to exert anti-tumorigenic and/or anti-angiogenic activities. A limitation to the therapeutic use of these matrikines is the large amount of purified recombinant proteins, in the milligram range in mice that should be administered daily throughout the experimental procedures. In the current study, we developed a new therapeutic approach based on tumstatin (NC1alpha3(IV)) overexpression in vivo in a mouse melanoma model. Gene electrotransfer of naked plasmid DNA (pDNA) is particularly attractive because of its simplicity, its lack of immune responsiveness and its safety. The pDNA electrotransfer in muscle mediates a substantial gene expression that lasts several months. A pVAX1(c) vector containing the tumstatin cDNA was injected into the legs of C57BL/6 mice and submitted to electrotranfer. Sera were collected at different times and tumstatin was quantified by ELISA. Tumstatin secretion reached a plateau at day 21 with an expression level of 12 mug/mL. For testing the effects of tumstatin expression on tumor growth in vivo, B16F1 melanoma cells were subcutaneously injected in mice 7 days after empty pVAX1(c) (Mock) or pVAX1(c)-tumstatin electrotransfer. Tumstatin expression triggered a large decrease in tumor growth and an increase in mouse survival. This new therapeutic approach seems promising to inhibit tumor progression in vivo.
Référence
Biochem Biophys Res Commun. 2013 Mar 22;432(4):549-52
